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Abstract
Background: KL-6, a human MUC1 mucin, is a sensitive biomarker for interstitial lung diseases including pulmonary
alveolar proteinosis (PAP). A correlation between MUC1 gene single nucleotide polymorphism (SNP) rs4072037
genotype and serum KL-6 levels has been reported. This study was aimed at investigating the correlation between
MUC1 SNP genotype, severity of disease and disease outcome in PAP.
Methods: Twenty four patients with PAP and 30 healthy volunteers were studied. MUC1 rs4072037 was detected
by using a real-time polymerase chain reaction (RT-PCR). Genotyping was performed by pyrosequencing. KL-6 levels
were measured in serum by Nanopia KL-6 assay (SEKISUI Diagnostics).
Results: The frequency of MUC1 rs4072037 alleles was significantly different between PAP patients and healthy
volunteers (PAP, A/A 46 %, A/G 54 %, G/G 0 %; healthy controls, A/A 30 %, A/G 40 %, G/G 30 %; p = 0.013). Serum
KL-6 levels were significantly higher in PAP patients than in controls (p < 0.0001), and significantly higher in PAP
patients with A/A genotype than in those with A/G genotype (p = 0.007). Patients with A/A genotype had higher
alveolar-arterial oxygen difference (A-aDO2) and lower DLco compared to those with A/G genotype (p = 0.027 and
p = 0.012, respectively). Multivariate analysis, Kaplan-Meier analysis and C statistics showed that the rs4072037 A/A
genotype was associated with higher rate of disease progression (HR: 5.557, p = 0.014).
Conclusions: MUC1 rs4072037 A/A genotype is associated with more severe pulmonary dysfunction and a higher
rate of disease progression in PAP patients.
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Background
Pulmonary alveolar proteinosis (PAP), first described in
1958 [1], is a rare syndrome (1–3 cases per million)
characterized by the intra-alveolar accumulation of sur-
factant lipoproteins [2]. The most common form is auto-
immune and is associated with the presence of
autoantibodies against GM-CSF [3–7].
KL-6 is a mucin-like glycoprotein belonging to the
MUC1 family [8]. KL-6 is moderately expressed in type
II pneumocytes and respiratory bronchiolar epithelial
cells and only weakly expressed in basal cells of the ter-
minal bronchiolar epithelium of normal lung tissues
[8]. Regenerating alveolar type II pneumocytes are the
primary cellular source of KL-6 in the affected lungs of
patients with interstitial lung diseases (ILD) [9–12].
Serum KL-6 is a sensitive biomarker for various ILD, such
as idiopathic pulmonary fibrosis, radiation pneumonitis,
drug-induced pneumonitis, hypersensitivity pneumonitis,
CTD-associated ILD, pulmonary sarcoidosis, and cystic
fibrosis [9, 13–16]. KL-6 levels have been found to be
elevated in serum and bronchoalveolar lavage (BAL) fluid
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of PAP patients at a concentration in BAL 3–5 fold higher
than in serum [12, 17].
It has been reported that the rs4072037 single nucleo-
tide polymorphism (SNP) in the exon 2 of the MUC1
gene is associated with inter-individual variability of
serum KL-6 levels [18, 19]. In addition, different distri-
bution of the SNP genotypes between Caucasian and
Japanese subjects has been observed [20].
The clinical utility of serum KL-6 in PAP has been
only partially investigated [12, 17, 21–25]. Recently our
group showed that serum KL-6 levels are a strong pre-
dictor of disease progression and of the necessity of
treatment with whole lung lavage (WLL) in PAP patients
[21]. However, the distribution of MUC1 SNP genotype
and how this affects serum KL-6 levels is unknown in
PAP patients.
The aim of this study was to investigate the correla-
tions between MUC1 SNP genotype distribution, serum
KL-6 levels, severity of disease and disease outcome in
PAP patients. Some of the results of this study have been
previously reported in the form of an abstract [26].
Methods
Disposition of the patients
We retrospectively studied 24 Caucasian patients with
autoimmune PAP followed in our institution between
2007 and 2014. The diagnosis of PAP was based on
characteristic BAL, high resolution computed tomog-
raphy (HRCT), and/or histopathologic findings [5, 27].
GM-CSF autoantibodies were detected in all patients
(Table 1). As a comparison group, 30 healthy controls
were also included. The study was approved by the local
IRB (approval number 10–4397). Written informed con-
sent was obtained from both patients and healthy
controls.
Definition of disease progression
Disease progression was defined as the necessity of treat-
ment with WLL during follow-up. The indication for
WLL was given on the basis of deterioration of self-
reported symptoms (worsening of dyspnea, cough, chest
pain and weight loss) and/or lung function (decrease in
FVC or DLco >10 % pred or increase in the A-aDO2 >
10 mmHg), and/or chest imaging (increase of the previ-
ous findings or appearance of new infiltrates characteris-
tic of PAP) since the last follow-up visit [21].
KL-6, GM-CSF autoantibody and other laboratory assays
Serum samples were obtained by venipuncture at
time of first evaluation and were stored at −80 °C
until analysis. Serum KL-6 was measured by NANO-
PIA® KL-6 assay (SEKISUI Diagnostics, UK; upper
limit of normal <458 U/mL as determined in 142
Caucasian healthy subjects). GM-CSF autoantibody
(Abs) concentration was measured according to Kitamura,
T., et al. [28]. Recombinant GM-CSF (Sargramostim,
Genzyme, Cambridge, USA) was used to coat plates, as
standard we used monoclonal human-anti-human GM-
CSF antibody (BI01049904) provided by Boehringer
Ingelheim, Germany. The detection limit of this assay is
0.2 μg/mL. GM-CSF Abs values <3 μg/mL are consid-
ered normal, 3–7 μg/mL intermediate, and >7 compat-
ible with autoimmune PAP, according to Inoue et al.
2008 [4]. LDH was routinely measured in serum (nor-
mal value for LDH in our laboratory < 225 IU/L).
DNA preparation and genotype analyses of MUC1
rs4072037
Genomic DNA was extracted from peripheral blood leu-
kocytes by using silica-membrane- based nucleic acid
purification Kit (Qiagen DNA Mini Kit, Qiagen, USA),
and stored at −80 °C before use. As previously described
[29], the rs4072037 genotype was determined using a
real-time polymerase chain reaction (RT-PCR) method.
We used a commercially available SNP genotyping assay
(TaqMan SNP Genotyping Assay C 27532642–10; Life
Technologies Corp. Carlsbad, California, USA) and the
Applied Biosystems 7500 Fast RT-PCR System (Life
Technologies Corp. Carlsbad, California, USA).
Table 1 Demographics and baseline characteristics of the
studied subjects
Variables PAP Controls p value
n = 24 n = 30
Demographics
Age, years 46 ± 2 41 ± 2 n.s.
Gender, male/female, n 14/10 11/19 n.s.b
Smoking history, Current/Non, n 9/15 4/26 0.06b
BMI (kg/m2) 26 ± 1 24 ± 1 n.s.
Pulmonary function
FVC (% pred) 80 ± 4 97 ± 7 <0.0001
FEV1 (% pred) 74 ± 3 93 ± 2 <0.0001
PaO2 (mmHg) 69 ± 3 84 ± 1 0.005
TLC (% pred) 81 ± 3 94 ± 3 0.025
SaO2 (%) 94 ± 1 95 ± 1 n.s.
A-aDO2 (mmHg) 40 ± 3 8 ± 1 <0.0001
DLco (% pred) 50 ± 21 86 ± 10 0.002
Biomarkers
GM-CSF autoantibody (μg/mL)a 52 ± 6 4 ± 1 <0.0001
KL-6 (U/mL)a 5004 ± 983 283 ± 19 0.0001
LDH (IU/L)a 312 ± 24 193 ± 6 <0.0001
Unless otherwise indicated, values are expressed as mean ± SE.
n.s. not significant
aThe cut-off of normality for each biomarker is reported in the methods
bFischer’s exact test, all other comparisons with student’s t-test
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Pulmonary function tests
Measurements included forced vital capacity (FVC),
forced expiratory volume in one second (FEV1), total
lung capacity (TLC), diffusing capacity of the lung for
carbon monoxide (DLco), partial pressure of oxygen in
arterial blood (PaO2), and alveolar-arterial oxygen gradi-
ent (A-aDO2). They were performed at time of the blood
sample collection. Values were expressed as percentages
of predicted normal values [30].
Statistics
Continuous variables were evaluated for a normal dis-
tribution with the Kolmogorov-Smirnov test. Paramet-
ric data are presented as mean ± standard error of
mean (SEM). Categorical variables are presented as
either a percentage of the total or numerically, as ap-
propriate. Comparison between two groups was done
with Student’s t-test or Wilcoxon’s rank test for con-
tinuous variables, Chi-squared or Fischer’s exact test
for categorical variables. Spearman’s or Pearson’s cor-
relation coefficient was obtained for correlations.
Pearson’s goodness-of-fit Chi-square test and Fisher’s
exact test were used to test for deviation from Hardy-
Weinberg equilibrium. Univariate and multivariate
Cox proportional hazard regression model was con-
ducted to study the independent effect of age, gender,
smoking history, ethnicity, MUC SNP genotypes, and
pulmonary function tests on the disease course. The
Kaplan-Meier method with log-rank test was used to
analyze whether MUC SNP genotypes were associated
with the disease outcome. The predictive value for
disease progression of each considered variable was
evaluated by Harrell's C statistic. P values of < 0.05
were considered statistically significant. All statistical
analyses were performed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Demographics and patients’ outcome
Demographics and baseline characteristics of all studied
subjects are shown in Table 1. The mean follow-up time
of PAP patients was 18 ± 2 months (Range 1–36) from
baseline blood sampling. All patients experiencing dis-
ease progression (n = 12) were treated with whole lung
lavage (WLL), three of them received multiple WLL (>2)
during follow up. At baseline, 21 patients had already re-
ceived at least one WLL before blood sampling. Of
them, 5 patients were in remission at time of blood
sampling.
Serum levels of KL-6
The distribution of serum KL-6 levels was normal (Z =
0.727, p = 0.67). Serum KL-6 levels were significantly
higher in PAP patients than in healthy controls (mean ±
SEM: 5004 ± 983 vs. 283 ± 19 U/mL, p < 0.0001), and
serum LDH levels were also higher in PAP patients than
in healthy controls (312 ± 24 vs. 193 ± 6 IU/L, p <
0.0001) (Fig. 1).
MUC1 SNP genotypes and biomarkers levels distribution
MUC1 rs4072037 allele A and G were in Hardy-
Weinberg equilibrium in the studied cohort (A =61 %,
G = 39 %, p = 0.8). The frequency of MUC1 rs4072037
SNP genotype was significantly different between PAP
patients and healthy controls (PAP: A/A 46 %, A/G 54 %
and G/G 0 %; healthy controls: A/A 30, A/G 40 and G/
G 30 %, p = 0.013) (Fig. 2).
Serum KL-6 levels were significantly higher in PAP pa-
tients with A/A genotype than in those with A/G geno-
type (8084 ± 1673 vs. 2397 ± 462 U/mL, p = 0.007),
whereas such genotype-related differences in KL-6 levels
were not seen in healthy controls (A/A: 251 ± 25, A/G:
267 ± 20, G/G: 337 ± 40 U/mL, p > 0.05 for all compari-
sons) (Fig. 3a).
Serum LDH levels were also significantly higher in
PAP patients with A/A genotype than in those with A/G
genotype (369 ± 38 vs. 263 ± 22 IU/L, p = 0.030), but
such differences were not seen in healthy controls (A/A:
200 ± 12, A/G: 185 ± 10, G/G: 196 ± 6 IU/L) (Fig. 3b).
MUC1 SNP genotype and pulmonary dysfunction
Patients with A/A genotype had a higher A-aDO2 gradi-
ent and a lower DLco compared to those with A/G
genotype (45 ± 4 vs. 35 ± 3 mmHg, p = 0.027; 39 ± 6 vs.
57 ± 3 %pred., p = 0.012, respectively) (Fig. 4). There
were no correlations between KL-6 serum levels with
age, BMI or GM-CSF autoantibody (data not shown).
Correlation between MUC1 SNP and disease outcome
PAP patients with A/A genotype had a significantly
higher disease progression rate than those with A/G
genotype (82 vs. 23 % p = 0.006) (Table 2). Kaplan-Meier





































Fig. 1 Comparison of serum levels of KL-6 (a) and LDH (b) in 30
healthy controls and in 24 PAP patients
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rs4072037 (A/A) with disease progression in PAP (log-
rank test, p = 0.024) (Fig. 5).
Univariate and multivariate analyses for predicting
disease outcome
We performed univariate and multivariate analysis to in-
vestigate the association of several factors with disease
progression. In the univariate analysis, MUC1 rs4072037
(A/A) was the strongest predictor of disease progression
(HR, 4.079; 95 % CI, 1.068–15.571; p = 0.040) followed
by PaO2, A-aDO2, DLco, serum KL-6 and LDH (all with
HR around 1) (Table 3). In the multivariate analysis,
MUC1 rs4072037 (A/A) and gender (male) were signifi-
cantly associated with disease progression after adjust-
ment for age, gender and A-aDO2 as covariates (HR,
5.557, p = 0.014 and HR, 5.986, p = 0.025), (Table 3).
Harrell's C statistic for predicting disease progression
significantly increased when MUC1 SNP rs4072037
(A/A) was included into a model with the only
remaining covariate gender (male) (C statistic, 0.939;
95 % CI, 0.848–1.030, p < 0.001) as compared to gender
(male) alone.
Discussion
The current study showed that the distribution of
MUC1 rs4072037 genotypes is different between PAP
patients and healthy controls and is correlated with
serum KL-6 levels. We also found that the rs4072037
(A/A) genotype is associated with severity of pulmonary
dysfunction and disease progression. To our knowledge,
this is the first report on a likely association between
MUC1 gene SNP, KL-6 levels and disease outcome in
Caucasian PAP patients.
It is known that the distribution of rs4072037 geno-
types in MUC1 influence serum KL-6 levels and that
the distribution of rs4072037 genotype in both healthy
subjects and patients with ILD varies with ethnicity,
the A/G genotype being more common in Caucasians
and the A/A genotype more common in Japanese [20].
In our study, the distribution of the rs4072037 geno-
types in healthy controls was different from the distri-
bution in CEU population (Utah residents with
ancestry from northern and western Europe popula-
tions), which is reported in the HapMap database
(International HapMap Project) [31]. In fact, in the
CEU population the G/G genotype is less frequent
than the A/A genotype (14 vs. 30 %), while in our co-
hort we found the same frequency for both genotypes
(30 %). This distribution is very similar to that re-
ported in the GIH (Gujarati Indians in Houston,
Texas) population, which shows a frequency of 26 %
for both A/A and G/G genotypes (International Hap-
Map Project) [31].
We did not observe the G/G genotype in our PAP pa-
tients. This finding could suggest a correlation between
the rs4072037 A allele and susceptibility to PAP, but fur-
ther exploration is needed.
With regard to the correlation between MUC
rs4072037 genotype and serum KL-6 levels, we found
that serum KL-6 levels were higher in PAP patients with
A/A genotype than in those with A/G genotype, whereas
0 20 40 60 80 100
PAP
controls
9 (30%) 12 (40%) 9 (30%)
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Fig. 2 Frequency of MUC1 rs4072037 SNP genotypes in the
studied subjects










































Fig. 3 Correlation of MUC1 SNP genotype with serum KL-6 levels (a) and serum LDH levels (b) in 30 healthy controls and in 24 PAP patients
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this was not observed in healthy controls. In a previous
study with Caucasians (Dutch cohort), KL-6 levels were
higher in serum of healthy controls and sarcoidosis pa-
tients carrying the G allele, with G homozygotes having
the highest levels, A homozygotes the lowest, and het-
erozygotes intermediate levels, which is compatible with
a gene-dose effect [19]. This gene-dose effect was not re-
ported by Horimasu et al. neither in Caucasians nor in
Japanese, because serum KL-6 levels varied according to
genotype in a non concordant way between healthy sub-
jects and ILD patients [20]. This point needs further
investigation.
MUC1 is an extracellular protein anchored to the epi-
thelial surface and involved in morphogenetic signal
transduction [32]. Rs4072037 SNP disrupts the physio-
logical functions of MUC1, due to alternative splicing of
the 59-region of exon 2 controlled by rs4072037, and ul-
timately results in failure of the physiological protection
of human tissue [33, 34].
The G allele in rs4072037 has been reported to be
protective against gastric cancer in the Han Chinese
and Caucasian population [35, 36]. The A allele, on
the contrary, seems to confer susceptibility to dry
eye syndrome and gastric cancer [33, 35–37]. We
found that serum KL-6 levels were lower in PAP pa-
tients carrying the G allele and that the G allele was
associated with better pulmonary function (lower A-
aDO2 and higher DLco) in PAP patients. In the
multivariate analysis, the model including MUC1
rs4072037 A/A genotype showed a significant associ-
ation with disease progression when added to age,
gender, smoking history and A-aDO2 as covariates.
We can only speculate on the meaning of our find-
ings. Accumulation of surfactant proteins, phospho-
lipids, and cell debris as well as mechanical stress
due to impaired alveolar surface tension are under-
lying mechanisms of epithelial damage in PAP [5].
Reactive hyperplasy of alveolar epithelial cells and al-
tered permeability of air-blood membrane are typical
pathologic findings in PAP [38]. Hyperproduction of
mucins, like KL-6, or cytokeratins, like CYFRA-21,
has been observed in PAP and is considered an
injury-repair response to airway epithelial damage
[11, 39]. It can be hypothesized that the hyperpro-
duction of aberrant MUC1 isoforms, linked to the
presence of rs4072037 (A) homozygosis can lead to
failure in epithelial repair and perpetuation of dam-
age in PAP. Apart from this intriguing hypothesis,
our results, if confirmed, could suggest a role of
MUC1 SNP genotype at least as a genetic biomarker
for routine clinical use in PAP.
Limitations of this study are the small sample size of
this cohort, and the lack of a validation cohort.
Table 2 Clinical characteristics and disease outcome of PAP
patients stratified according to MUC1 rs4072037 gentype
Variables MUC1 rs4072037 genotype p
valueA/A A/G
n = 11 n = 13
Age, years 46 ± 3 46 ± 4 n.s.
Gender, male/female, n 6/5 8/5 n.s.d
Smoking history, Current/Non, n 10/1 8/5 n.s.d
BMI (kg/m2) 25 ± 2 27 ± 1 n.s.
Outcome
- Disease progressiona, n (%) 9 (82) 3 (23) 0.006d
- Death, n (%)b 1 (9) 2 (15) 0.90d
- Remission, n (%) 1 (9) 8 (61) 0.07
Treatment, (yes/no)
- Repeated WLL (>2)
during follow-up, n
3 0 0.055d
- cumulative number of WLL 7.3 ± 3.1 4.3 ± 1.2 0.359
FVC (% pred) 79 ± 6 82 ± 4 n.s.
FEV1 (% pred) 73 ± 4 74 ± 4 n.s.
PaO2 (mmHg) 67 ± 6 72 ± 3 n.s.
TLC (% pred) 79 ± 6 83 ± 4 n.s.
SaO2 (%) 93 ± 1 94 ± 1 n.s.
A-aDO2 (mmHg) 45 ± 4 35 ± 3 0.027
DLco (% pred) 39 ± 6 60 ± 3 0.012
GM-CSF autoantibody (μg/mL)c 51 ± 11 53 ± 8 n.s.
KL-6 (U/mL)c 8084 ± 1673 2399 ± 462 0.007
LDH (IU/L)c 369 ± 38 263 ± 22 0.030
Unless otherwise indicated, values are expressed as mean ± SE
n.s. not significant
aDisease progression was defined as necessity of whole lung lavage on the
basis of deterioration of self-reported symptoms (worsening of dyspnea,
cough, chest pain and weight loss) and/or lung function (decrease in FVC or
DLco >10 % pred or increase in the A-aDO2 > 10 mmHg), and/or chest
imaging (increase of the previous findings or appearance of new infiltrates
characteristic of PAP) since the last follow-up visit
bOne death followed whole lung lavage, one was related to alcoholic liver
cirrhosis and one to lung cancer



































Fig. 4 Correlation of MUC1 SNP genotype with A-aDO2 (a) and DLco
(b) in PAP patients
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Moreover, we cannot exclude that previously received
WLL could have an influence on serum KL-6 concentra-
tion and therefore on their correlation with MUC1
genotypes.
Conclusion
On the basis of our results, MUC1 SNP (rs4072037)
genotype may be correlated with serum KL-6 levels, the
severity of pulmonary dysfunction and disease progres-
sion in PAP. Further multicentric studies involving larger
populations of different ethnicities are needed to validate
these results.
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Table 3 Univariate and multivariate Cox proportional hazard
model evaluating predictors for disease progression
Variables β HR (95 % CI) p value
Univariate analysis
rs4072037 (A/A) 1.405 4.079 (1.068–15.571) 0.040
Age (continuous) −0.001 0.999 (0.944–1.057) 0.966
Gender (male) 1.323 3.755 (0.808–17.444) 0.091
Smoking history
(current smoker)
3.480 32.452 (0.101–10395.609) 0.237
BMI (continuous) −0.056 0.945 (0.837–1.068) 0.367
FVC (continuous) −0.042 0.959 (0.918–1.001) 0.058
PaO2 (continuous) −0.126 0.882 (0.804–0.967) 0.008
A-aDO2 (continuous) 0.086 1.090 (1.015–1.171) 0.017
DLco (continuous) −0.054 0.947 (0.906–0.997) 0.017
GM-CSF autoantibody
(continuous)
−0.023 0.975 (0.938–1.014) 0.201
KL-6 (continuous) 0.001 1.00 (0.99–1.00) 0.014
LDH (continuous) 0.006 1.006 (1.000–1.011) 0.022
Multivariate analysisa
rs4072037 (A/A) 1.715 5.557 (1.412–21.869) 0.014
Gender (male) 1.789 5.986 (1.255–28.557) 0.025
aHazard ratio calculated by the Cox proportional hazard model backward
stepwise considering the following variables in the model: age, gender,
smoking history (current smoker), baseline FVC (%),baseline DLCO (%), PaO2,
KL-6 and LDH










No. a t risk
A/G group:   13  12       10      10
A/A group:   11   7        3       2



















Fig. 5 Kaplan-Meier analysis showing disease progression according
to MUC1 SNP genotype in 24 PAP patients
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